HealthcareServices

Global Chemotherapy-Induced Neutropenia Treatment Market Forecast 2026–2035: Long-Term Growth Insights

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chemotherapy-induced neutropenia treatment market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Chemotherapy-Induced Neutropenia Treatment Market?

The market size for chemotherapy-induced neutropenia treatment has demonstrated substantial growth over recent years. It is anticipated to expand from $0.62 billion in 2025 to $0.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.3%. The historic growth in this sector is due to factors such as the increasing incidence of chemotherapy-induced neutropenia, the expansion of aggressive cancer treatment protocols, the availability of colony-stimulating factors, improved clinical monitoring practices, and the growth of oncology treatment facilities.

The chemotherapy-induced neutropenia treatment market size is anticipated to demonstrate robust growth over the next few years. It is predicted to expand to $0.79 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.1%. The expansion during the forecast period can be attributed to the rising adoption of long-acting growth factors, an increasing focus on outpatient neutropenia management, the broadened usage of biosimilar g-csf, growing investments in infection prevention strategies, and advancements in immunomodulatory therapies. Key trends expected in the forecast period include the increasing uptake of prophylactic g-csf therapy, a rise in the use of early intervention treatment models, a growing emphasis on infection risk reduction, the expansion of personalized neutropenia management, and enhanced monitoring of white blood cell levels.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp

Which Drivers Are Supporting The Rise Of The Chemotherapy-Induced Neutropenia Treatment Market?

The rising prevalence of cancer is anticipated to drive expansion in the chemotherapy-induced neutropenia treatment market in the foreseeable future. Cancer is defined as a collection of illnesses marked by the uncontrolled multiplication and dispersal of aberrant cells throughout the body. This increase in cancer diagnoses is linked to the aging demographic, given that elderly individuals face a greater likelihood of developing cancer due to the gradual accumulation of genetic mutations and a diminishing immune system functionality. Treatment for chemotherapy-induced neutropenia supports cancer care by lowering the chances of infection via immune system bolster, enabling patients to proceed with chemotherapy with fewer delays. It improves treatment results by cutting down on complications, consequently boosting overall patient safety and their quality of life. As an illustration, in July 2024, data from the Australian Institute of Health and Welfare, an Australian government body, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 new cases daily, with males accounting for about 55% of these diagnoses. Consequently, the growing occurrence of cancer is a key factor propelling the expansion of the chemotherapy-induced neutropenia treatment market.

What Segments Are Identified Within The Structure Of The Chemotherapy-Induced Neutropenia Treatment Market?

The chemotherapy-induced neutropenia treatment market covered in this report is segmented –

1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types

2) By Route of Administration: Subcutaneous, Intravenous

3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics

2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim

3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion

4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy

Which Competitive Trends Are Impacting The Structure Of The Chemotherapy-Induced Neutropenia Treatment Market?

Leading companies within the chemotherapy-induced neutropenia treatment market are concentrating on developing and securing approvals for innovative products, such as long-acting formulations, with the goal of enhancing patient convenience, decreasing dosing frequency, and improving treatment adherence. Long-acting formulations are drug preparations designed to release active ingredients slowly over an extended period, thereby reducing the need for frequent administration. For example, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for Udenyca Onbody, a novel, ready-to-use on-body injector. This device, featuring a long-acting formulation, automatically delivers pegfilgrastim approximately 27 hours after chemotherapy, eliminating the necessity for a next-day injection. Udenyca Onbody contributes to a better patient experience by ensuring timely prophylactic treatment of chemotherapy-induced neutropenia while simultaneously reducing clinic visits and boosting adherence.

Which Major Industry Participants Are Leading The Chemotherapy-Induced Neutropenia Treatment Market Growth?

Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-neutropenia-treatment-global-market-report

Which Region Is Projected To Lead The Chemotherapy-Induced Neutropenia Treatment Market During The Forecast Period?

North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chemotherapy-Induced Neutropenia Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp

Browse Through More Reports Similar to the Global Chemotherapy-Induced Neutropenia Treatment Market 2026, By The Business Research Company

Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Chemotherapy Induced Myelosuppression Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-myelosuppression-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795